Vaccí contra la COVID-19: diferència entre les revisions

Contingut suprimit Contingut afegit
Línia 111:
|locations=Rússia, Bielorússia<ref>{{ref-notícia|títol=Клинические исследования вакцины "Спутник V" в Беларуси начались раньше |url=https://www.belta.by/society/view/klinicheskie-issledovanija-vaktsiny-sputnik-v-v-belarusi-nachalis-ranshe-408737-2020/ |obra=BELTA |data= 29 setembre 2020 |llengua=ru}}</ref> Índia,<ref>{{ref-notícia|cognom1=Kumar |nom1=Shivani |títol=Sputnik-V from Russia arrives in India for clinal trials |url=https://www.hindustantimes.com/india-news/sputnik-v-from-russia-arrives-in-india-for-clinal-trials/story-b8k3Ecncxw2RBTrIxOiqxO.html |obra=Hindustan Times |data=1 desembre 2020}}</ref><ref>{{ref-notícia|títol=Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune |url=https://indianexpress.com/article/india/clinical-trial-17-volunteers-given-russias-sputnik-v-covid-19-vaccine-in-pune-7094153/ |obra=The Indian Express |data=6 desembre 2020}}</ref> Venezuela,<ref>{{ref-notícia|títol=Sputnik V's Clinical Trials in Venezuela: What We Do and Do Not Know |url=https://pulitzercenter.org/reporting/sputnik-vs-clinical-trials-venezuela-what-we-do-and-do-not-know-spanish |obra=Pulitzer Center |data= 5 novembre 2020}}</ref> UAE<ref>{{ref-notícia|títol=UAE begins trials of Russia's Sputnik V Covid-19 vaccine |url=https://www.clinicaltrialsarena.com/news/uae-begins-sputnik-v-trial/ |obra=ClinicalTrials |data= 8 gener 2021}}</ref>|duration=Ago 2020 - Mai 2021}}
|{{CovidVacNum|Sputnik V}}
|- valign="top"
|'''[[Vacuna de Moderna contra la COVID-19|Vacuna de Moderna]]'''<wbr /><ref name="NCT04470427">{{ref-web|títol=A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04470427 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04470427 |data= 14 juliol 2020 |access-date= 27 juliol 2020}}</ref><ref name="palca">{{ref-notícia|cognom1=Palca |nom1=Joe |títol=COVID-19 vaccine candidate heads to widespread testing in U.S. |url=https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people |consulta= 27 juliol 2020 |obra=NPR |data= 27 juliol 2020 | name-list-format = vanc}}</ref><br />[[Moderna]], [[National Institute of Allergy and Infectious Diseases|NIAID]], [[Biomedical Advanced Research and Development Authority|BARDA]], [[Coalició per a les Innovacions en Preparació per Epidèmies|CEPI]]
|EUA
|[[Vacuna d'ARN|V. d'ARN]] (dispersió de [[Nanopartícula lipídica sòlida|nanopartícules lipídiques]]) contenint [[ARNmod]]<wbr/><ref name="NCT04283461">{{ref-web|títol=Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04283461 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |id=NCT04283461 |data= 16 març 2020 |access-date= 5 març 2021}}</ref>
|2 dosis<br />4 setm.<wbr/><ref>{{ref-notícia|data= 26 gener 2021 |títol=WHO experts issue recommendations on Moderna COVID-19 vaccine |url=https://www.reuters.com/article/health-coronavirus-who-moderna-idUSL8N2K131U |obra=[[Reuters]] |lloc=[Ginebra] |access-date= 5 març 2021}}</ref>{{efn-la|name=who-extended-interval-rna-vaccines}}
| data-sort-value="-20" | -20±5{{nbsp}}°C<wbr/><ref>{{ref-web |type=Fact sheet |url=https://www.fda.gov/media/144637/download |títol=Fact Sheet for Healthcare Providers Administering Vaccine |editor=[[Food and Drug Administration]] |data= desembre 2020 |llengua=anglès |consulta= 30 març 2021}}</ref><br/>([[congelador]])
|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Intervencional; estudi aleatori, controlat amb placebo, per a l'eficàcia, la seguretat i la immunogenicitat.|status=El 15 de novembre de 2020 es van anunciar resultats positius d'una anàlisi provisional.<ref>{{ref-web|títol=Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine |url=https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine |website=National Institutes of Health (NIH) |data= 15 novembre 2020}}</ref> i publicat el 30 de desembre de 2020 amb una eficàcia global del 94,1%.<ref name="mRNA1273 Vaccine">{{ref-publicació|vauthors=Baden L, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector S, Rouphael N, Creech B, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham B, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Sahly H, Han S, Ivarsson M, Miller J, Zaks T|display-authors=6 |títol= Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine|publicació=New England Journal of Medicine |data= desembre 2020 |doi= 10.1056/NEJMoa2035389|pmid=33378609 |doi-access=free}}</ref>|locations=EUA|duration=Jul 2020{{snd}}Oct 2022}}
|{{CovidVacNum|Moderna}}
|- valign="top"
|'''[[BBIBP-CorV]]'''<wbr /><ref name="ChiCTR2000034780">{{ref-publicació|cognom1=Chen |nom1=Wei |cognom2=Al Kaabi |nom2=Nawal |títol=A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) |publicació=Chinese Clinical Trial Registry |data= 18 juliol 2020 |url=http://www.chictr.org.cn/showprojen.aspx?proj=56651 |access-date= 15 agost 2020 |name-list-style=vanc}}</ref><br />[[China National Pharmaceutical Group|Sinopharm]]: Institut de Productes Biològics de Pequín, Institut de Productes Biològics de Wuhan
Linha 127 ⟶ 119:
|{{ClinicalStudyInfo|align=left|phase=3|participants=48000|description=Aleatori, doble cec, controlat amb placebo en paral·lel, per avaluar l'eficàcia de seguretat i protecció.|status=L'anàlisi interna de Sinopharm va indicar una eficàcia del 79%.<ref>{{ref-notícia|cognom1=Wee|nom1=Sui-Lee|cognom2=Qin|nom2=Amy|data=2020-12-30|títol=A Chinese Covid-19 Vaccine Has Proved Effective, Its Maker Says|obra=The New York Times|url=https://www.nytimes.com/2020/12/30/business/china-vaccine.html|access-date=2020-12-30|issn=0362-4331}}</ref>|locations=[[Emirats Àrabs Units|EAU]], [[Bahrain]], [[Jordània]],<ref>{{ref-web|cognom1=Yang |nom1=Yunkai |títol=A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT04510207 |website=[[ClinicalTrials.gov]] |access-date= 15 setembre 2020 |name-list-style=vanc |arxiudata= 14 setembre 2020 |arxiuurl=https://web.archive.org/web/20200914040138/https://clinicaltrials.gov/ct2/show/NCT04510207 |url-status=live}}</ref> [[Argentina]],<ref>{{ref-web|títol=Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04560881?term=vaccine&cond=covid-19&draw=2&rank=3 |website=[[ClinicalTrials.gov]] |access-date= 28 setembre 2020}}</ref> [[Marroc]],<ref>{{ref-web|títol=A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) |url=http://www.chictr.org.cn/showprojen.aspx?proj=62581 |website=www.chictr.org.cn |editor=Chinese Clinical Trial Register (ChiCTR) |access-date=15 desembre 2020}}</ref> [[Perú]]<ref>{{ref-web|títol=Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers|url=https://www.msn.com/en-au/lifestyle/wellbeing/bahrain-announces-emergency-approval-for-use-of-covid-19-vaccine-candidate/ar-BB1aEciR |access-date= 3 novembre 2020|website=MSN|agency=Reuters}}</ref>|duration=Jul 2020 – Jul 2021}}
|{{CovidVacNum|BBIBP-CorV}}
|- valign="top"
|'''[[Vacuna de Moderna contra la COVID-19|Vacuna de Moderna]]'''<wbr /><ref name="NCT04470427">{{ref-web|títol=A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04470427 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |type=Registry |id=NCT04470427 |data= 14 juliol 2020 |access-date= 27 juliol 2020}}</ref><ref name="palca">{{ref-notícia|cognom1=Palca |nom1=Joe |títol=COVID-19 vaccine candidate heads to widespread testing in U.S. |url=https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people |consulta= 27 juliol 2020 |obra=NPR |data= 27 juliol 2020 | name-list-format = vanc}}</ref><br />[[Moderna]], [[National Institute of Allergy and Infectious Diseases|NIAID]], [[Biomedical Advanced Research and Development Authority|BARDA]], [[Coalició per a les Innovacions en Preparació per Epidèmies|CEPI]]
|EUA
|[[Vacuna d'ARN|V. d'ARN]] (dispersió de [[Nanopartícula lipídica sòlida|nanopartícules lipídiques]]) contenint [[ARNmod]]<wbr/><ref name="NCT04283461">{{ref-web|títol=Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04283461 |website=[[ClinicalTrials.gov]] |editor=[[United States National Library of Medicine]] |id=NCT04283461 |data= 16 març 2020 |access-date= 5 març 2021}}</ref>
|2 dosis<br />4 setm.<wbr/><ref>{{ref-notícia|data= 26 gener 2021 |títol=WHO experts issue recommendations on Moderna COVID-19 vaccine |url=https://www.reuters.com/article/health-coronavirus-who-moderna-idUSL8N2K131U |obra=[[Reuters]] |lloc=[Ginebra] |access-date= 5 març 2021}}</ref>{{efn-la|name=who-extended-interval-rna-vaccines}}
| data-sort-value="-20" | -20±5{{nbsp}}°C<wbr/><ref>{{ref-web |type=Fact sheet |url=https://www.fda.gov/media/144637/download |títol=Fact Sheet for Healthcare Providers Administering Vaccine |editor=[[Food and Drug Administration]] |data= desembre 2020 |llengua=anglès |consulta= 30 març 2021}}</ref><br/>([[congelador]])
|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Intervencional; estudi aleatori, controlat amb placebo, per a l'eficàcia, la seguretat i la immunogenicitat.|status=El 15 de novembre de 2020 es van anunciar resultats positius d'una anàlisi provisional.<ref>{{ref-web|títol=Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine |url=https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine |website=National Institutes of Health (NIH) |data= 15 novembre 2020}}</ref> i publicat el 30 de desembre de 2020 amb una eficàcia global del 94,1%.<ref name="mRNA1273 Vaccine">{{ref-publicació|vauthors=Baden L, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector S, Rouphael N, Creech B, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham B, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Sahly H, Han S, Ivarsson M, Miller J, Zaks T|display-authors=6 |títol= Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine|publicació=New England Journal of Medicine |data= desembre 2020 |doi= 10.1056/NEJMoa2035389|pmid=33378609 |doi-access=free}}</ref>|locations=EUA|duration=Jul 2020{{snd}}Oct 2022}}
|{{CovidVacNum|Moderna}}
|- valign="top"
|'''[[Vacuna de Johnson & Johnson contra la COVID-19|Vacuna de Johnson & Johnson]]'''<ref name=":2">{{ref-web|títol=A Study of Ad26.COV2.S in Adults|url=https://clinicaltrials.gov/ct2/show/NCT04436276|access-date= 23 agost 2020|website=[[ClinicalTrials.gov]]|data= 4 agost 2020|arxiudata= 16 setembre 2020|arxiuurl=https://web.archive.org/web/20200916063346/https://clinicaltrials.gov/ct2/show/NCT04436276|url-status=live}}</ref><ref name=":3">{{ref-web|títol=A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants|url=https://clinicaltrials.gov/ct2/show/NCT04505722|url-status=live|arxiuurl=https://web.archive.org/web/20200926145744/https://clinicaltrials.gov/ct2/show/NCT04505722|arxiudata= 26 setembre 2020|website=ClinicalTrials.gov|editor=US National Library of Medicine}}</ref>